Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment
 
  • Details

Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment

Journal
Clinical Drug Investigation
Journal Volume
39
Journal Issue
12
Pages
1195-1203
Date Issued
2019
Author(s)
Yeh N.-L.
Hsu C.-Y.
TSEN-FANG TSAI  
HSIEN-YI CHIU  
DOI
10.1007/s40261-019-00849-7
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073967425&doi=10.1007%2fs40261-019-00849-7&partnerID=40&md5=3c134f4568f054e5919fd3387d139cb5
https://scholars.lib.ntu.edu.tw/handle/123456789/517534
Abstract
Background and Objective: Immunotherapy could change the complex host-microbial interactions. We aimed to investigate the dynamics of gut microbiome in response to secukinumab [an interleukin (IL)-17 inhibitor] and ustekinumab (an IL-12/23 inhibitor) therapy and its association with treatment response in psoriasis. Methods: This observational, longitudinal study collected a total of 114 fecal samples from 12 healthy controls and 34 patients with psoriasis at baseline and 3 and 6?months after secukinumab (n = 24) or ustekinumab treatment (n = 10) and gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA. Results: Secukinumab treatment causes more profound alterations in gut microbiome, including increases in the relative abundance of phylum Proteobacteria and decreases in Bacteroidetes and Firmicutes, than ustekinumab treatment. The relative abundance of family Pseudomonadaceae, family Enterobacteriaceae and order Pseudomonadales also increased significantly following secukinumab therapy. In contrast, there was no significant change in gut microbiome composition following ustekinumab treatment, and only genus Coprococcus significantly increased after 6?months of ustekinumab therapy. Moreover, we observed significant differences in baseline gut microbiome between responders and non-responders to secukinumab treatment. Conclusion: These results indicate that gut microbiome is altered differently after anti-IL17 and anti-IL12/23 treatment. Secukinumab (anti-IL17) therapy is associated with distinct and more profound gut microbiome shifts than ustekinumab therapy (anti-IL 12/23) in patients with psoriasis. Moreover, gut microbiome would serve as potential biomarkers of response to secukinumab treatment. ? 2019, Springer Nature Switzerland AG.
SDGs

[SDGs]SDG3

Other Subjects
genomic DNA; RNA 16S; secukinumab; ustekinumab; interleukin 12; interleukin 17; interleukin 23; monoclonal antibody; secukinumab; ustekinumab; Aeromonas; Article; Bacteroidetes; controlled study; Coprococcus; Enterobacteriaceae; Firmicutes; gene sequence; host microbe interaction; human; intestine flora; longitudinal study; major clinical study; next generation sequencing; nonhuman; observational study; priority journal; Proteobacteria; Pseudomonadaceae; Pseudomonadales; psoriasis; Psoriasis Area and Severity Index; psoriatic arthritis; adult; drug effect; female; intestine flora; male; microbiology; middle aged; psoriasis; Adult; Antibodies, Monoclonal, Humanized; Female; Gastrointestinal Microbiome; Humans; Interleukin-12; Interleukin-17; Interleukin-23; Longitudinal Studies; Male; Middle Aged; Psoriasis; Ustekinumab
Publisher
Springer International Publishing
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science